tetano
Editor, Senior Moderator
Enferm Infecc Microbiol Clin
. 2021 Aug 27.
doi: 10.1016/j.eimc.2021.07.009. Online ahead of print.
[The new generation of messenger RNA (mRNA) vaccines against influenza]
[Article in Spanish]
Jordi Reina[SUP] 1 [/SUP]
Affiliations
Abstract
in English, Spanish
Today there are multiple types of flu vaccines. The emergence of nucleic acid technology used in vaccines against SARS-CoV-2 suggests its future application against this infection. Against influenza, two types of vaccines have been developed based on messenger RNA (mRNA): conventional or non-replicative and self-amplifying or replicative (auRNA), both included in lipid nanoparticles. Animal studies carried out with the former have shown their strong capacity to induce Th-1 antibodies and cellular immunity against influenza haemagglutinin (HA) with few side effects. Human trials have shown 87% seroconversion and 100% seroprotection. The auRNA vaccines have obtained similar results in animals but at a concentration 64 times lower than the conventional one. Vaccines based on mRNA platforms meet the WHO requirements for next generation influenza vaccines.
Keywords: Flu; Vaccine efficacy; messenger RNA vaccines.
. 2021 Aug 27.
doi: 10.1016/j.eimc.2021.07.009. Online ahead of print.
[The new generation of messenger RNA (mRNA) vaccines against influenza]
[Article in Spanish]
Jordi Reina[SUP] 1 [/SUP]
Affiliations
- PMID: 34483424
- PMCID: PMC8397276
- DOI: 10.1016/j.eimc.2021.07.009
Abstract
in English, Spanish
Today there are multiple types of flu vaccines. The emergence of nucleic acid technology used in vaccines against SARS-CoV-2 suggests its future application against this infection. Against influenza, two types of vaccines have been developed based on messenger RNA (mRNA): conventional or non-replicative and self-amplifying or replicative (auRNA), both included in lipid nanoparticles. Animal studies carried out with the former have shown their strong capacity to induce Th-1 antibodies and cellular immunity against influenza haemagglutinin (HA) with few side effects. Human trials have shown 87% seroconversion and 100% seroprotection. The auRNA vaccines have obtained similar results in animals but at a concentration 64 times lower than the conventional one. Vaccines based on mRNA platforms meet the WHO requirements for next generation influenza vaccines.
Keywords: Flu; Vaccine efficacy; messenger RNA vaccines.